Headlines

Cancer death rate continues to decline amid progress, challenges, researchers report

 3 months ago       1007 Views

Cancer death rate continues to decline amid progress, challenges, researchers report.

The Gilbertsville, Pa., resident also enrolled in a clinical trial of Keytruda, the immune-boosting drug made by Merck.

Today, three years later, he has no evidence of cancer.

Keytruda and McCone are highlighted in the annual cancer progress report issued Wednesday by the Philadelphia-based American Association for Cancer Research.

Moreover, in the past year, the FDA has approved nine new cancer drugs and expanded the approved uses for eight more.

Two of the new drugs are in the revolutionary class of immunotherapies, called “checkpoint inhibitors,” that includes Keytruda.

(And the report was finalized just before the Aug. 30 approval of the world’s first genetically engineered immune therapy, Novartis Pharmaceuticals’ T-cell treatment for pediatric leukemia, which was pioneered at the University of Pennsylvania and Children’s Hospital of Philadelphia.)

“Since I was in medical school in the late 1970s, I have seen a transformation in cancer care,” AACR president Michael A. Caligiuri says in the executive summary.

“This change is a result of tremendous advances in basic and applied research.” Of course, it’s not all good news.

HPV causes cervical cancer as well as rarer malignancies including head and neck cancers like McCone’s.


Author: @DailyCupofYoga

Source: philly.com